Skip to main content
. Author manuscript; available in PMC: 2021 Apr 14.
Published in final edited form as: Circulation. 2020 Feb 12;141(15):1214–1224. doi: 10.1161/CIRCULATIONAHA.119.045093

Table 2.

Base Case Results

Usual Care Tafamidis
Healthcare Outcomes
Survival, life years (undiscounted) 3.46 (2.88 – 4.25) 5.43 (4.17 – 6.76)
Survival, life years (discounted) 3.23 (2.73 – 3.84) 4.83 (3.82 – 5.79)
Incremental life years (discounted) Comparator 1.60 (0.48 – 2.47)
Quality-adjusted survival, QALYs (discounted) 2.19 (1.94 – 2.56) 3.48 (2.85 – 4.15)
Incremental QALYs (discounted) Comparator 1.29 (0.47 – 1.75)
Cardiovascular Hospitalizations, number 2.36 (1.87 – 3.02) 2.53 (1.78 – 3.43)
Direct Healthcare Costs
Lifetime Healthcare Costs, 2019 USD (discounted) 126,000 (105,000 – 157,000) 1,262,000 (996,000 – 1,515,000)
 Spending on Tafamidis - 1,086,000 (861,000 – 1,303,000)
 Spending on CV Hospitalizations 34,000 (26,000 – 46,000) 34,000 (23,000 – 47,000)
 Background Healthcare Costs 92,000 (77,000 – 113,000) 142,000 (110,000 – 174,000)
Incremental healthcare costs, 2019 USD (discounted) Comparator $1,135,000 (872,000–1,377,000)
ICER, USD per life-year gained Comparator $709,000 (547,000 – 1,943,000)
ICER, USD per QALY gained Comparator $880,000 (697,000–1,564,000)

Abbreviations: ICER = incremental cost-effectiveness ratio; USD = United States Dollar; QALY = quality-adjusted life year.